Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Schadendorf

Showing results (1-10 of 877) with videos related to

Pageof 88
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 29, 2011
[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma]Dirk Schadendorf
European Journal of Cancer (Oxford, England : 1990)|December 8, 2021
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 5, 2014
[Working Group on Dermatological Oncology -- a dermatological success story]Dirk Schadendorf
Oncology Research and Treatment|October 26, 2016
[Entscheidungsfindung für die klinische Praxis: Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim Melanom]Dirk Schadendorf
Seminars in Oncology|October 31, 2002
Gene-based therapy of malignant melanomaDirk Schadendorf
The Journal of Investigative Dermatology|April 17, 2009
Peroxisome proliferator-activating receptors: a new way to treat melanoma?Dirk Schadendorf
Future Oncology (London, England)|July 24, 2025
COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanomaDirk Schadendorf
The Journal of Investigative Dermatology|March 5, 2002
The use of histamine in cancer immunotherapyDirk Schadendorf
Molecular Oncology|February 25, 2011
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Iris Helfrich, Dirk Schadendorf
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 25, 2002
Gene-based immunotherapy of skin cancersYuansheng Sun, Dirk Schadendorf
Pageof 88

Showing results (1-10 of 877) with videos related to

Sort By:
Pageof 88
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 29, 2011
[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma]Dirk Schadendorf
European Journal of Cancer (Oxford, England : 1990)|December 8, 2021
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 5, 2014
[Working Group on Dermatological Oncology -- a dermatological success story]Dirk Schadendorf
Oncology Research and Treatment|October 26, 2016
[Entscheidungsfindung für die klinische Praxis: Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim Melanom]Dirk Schadendorf
Seminars in Oncology|October 31, 2002
Gene-based therapy of malignant melanomaDirk Schadendorf
The Journal of Investigative Dermatology|April 17, 2009
Peroxisome proliferator-activating receptors: a new way to treat melanoma?Dirk Schadendorf
Future Oncology (London, England)|July 24, 2025
COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanomaDirk Schadendorf
The Journal of Investigative Dermatology|March 5, 2002
The use of histamine in cancer immunotherapyDirk Schadendorf
Molecular Oncology|February 25, 2011
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Iris Helfrich, Dirk Schadendorf
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 25, 2002
Gene-based immunotherapy of skin cancersYuansheng Sun, Dirk Schadendorf
Pageof 88